Denise Yardley, MD, Tennessee Oncology

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Denise Yardley, MD, discusses treatment considerations for patients with advanced breast cancer who have visceral metastases.

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Denise Yardley, MD, discusses the impact of biosimilars on breast cancer treatment.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the importance of tailoring treatment approaches to the different subtypes of patients with breast cancer.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the RESPECT trial in HER2-positive breast cancer.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.